<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04301141</url>
  </required_header>
  <id_info>
    <org_study_id>0c Valmaggia</org_study_id>
    <nct_id>NCT04301141</nct_id>
  </id_info>
  <brief_title>Using Virtual Reality to Treat Social Anxiety in Autistic Adolescents</brief_title>
  <official_title>Using Virtual Reality Assisted Therapy for Social Anxiety in Adolescents With Autism Spectrum Disorder: A Case Series</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>South London and Maudsley NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the feasibility and acceptability of virtual reality assisted cognitive
      behavioural therapy for the treatment of social anxiety in autistic adolescents. Five
      adolescents will receive the intervention and a parent/caregiver of each adolescent will be
      asked to act as informants on some questionnaires and interviews.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Difficulties interacting with others in social situations is a core characteristic of autism
      spectrum disorder (ASD). These difficulties are intensified by social anxiety - commonly
      experienced in autistic adolescents. A promising psychological treatment is cognitive
      behavioural therapy (CBT), but there are constraints in its use for the autistic population.
      For example, CBT requires patients to imagine being in a social situation that would cause
      anxiety, but autistic people often experience difficulties with imagination. The use of
      virtual reality (VR) in CBT may help to lessen such constraints. VR uses 3D
      computer-generated visual environments displayed through a head-mounted display. The images
      are synchronised to the movements of the user such that they experience feeling immersed in
      the virtual scene. The virtual scene can involve social scenarios, making it an ideal tool
      for eliciting social anxiety in the treatment setting. The investigators can see if these
      virtual scenarios are indeed eliciting social anxiety by recording physiological responses
      (e.g. heart rate) in parallel with patients' anxiety ratings during exposure. This is
      important for CBT to be effective.

      This study will test the feasibility and acceptability of VR-assisted CBT, combined with the
      use of physiological measurements, in autistic adolescents experiencing social anxiety. The
      therapy will typically consist of 8-20 weekly sessions and will be delivered by clinical
      psychologists in local mental health services. Conventional outcome measures will be used and
      feedback from youth and their parents/caregivers will be requested. The results of this study
      may lead to modification of the treatment and research methods. They will inform a later
      pilot randomised controlled trial.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VR session completion rate.</measure>
    <time_frame>Through study completion, anticipated duration of 9 months.</time_frame>
    <description>This will be indicated by the proportion of the patients who commenced the VR component that completed it. Completion is defined as 75% attendance of the total VR exposure sessions recommended by the therapist. Not all therapy sessions involve VR exposure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of participant identification.</measure>
    <time_frame>End of recruitment period, maximum duration 7.5 months from study start date.</time_frame>
    <description>Number of patients deemed eligible to partake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recruitment rate.</measure>
    <time_frame>Through study completion, anticipated duration of 9 months.</time_frame>
    <description>Proportion of eligible patients successfully recruited (i.e. the proportion of patients approached for whom consent was provided to participate).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participant retention.</measure>
    <time_frame>Baseline; end of therapy up to 20 weeks; follow-up: 6 weeks post-treatment.</time_frame>
    <description>The proportion of participants completing each stage of the study (i.e. baseline assessments/measures, therapy and therapy measures, and post-treatment assessments/measures).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy attendance.</measure>
    <time_frame>End of therapy up to 20 weeks.</time_frame>
    <description>The proportion of sessions recommended by the therapist that the patient attended.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and number of sessions.</measure>
    <time_frame>Through study completion, anticipated duration of 9 months.</time_frame>
    <description>The number and frequency of VR-CBT sessions deemed suitable for each patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects.</measure>
    <time_frame>During and immediately after the intervention.</time_frame>
    <description>This is a 25-item self-report questionnaire. Participants are asked to rate the extent they agree with each statement using a 5-point Likert scale (0 = Not at all; 4 = Very much). Statements refer to their experience of the therapy and whether taking part has caused any distress. Higher scores indicate increased adverse effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experience and opinions on the intervention.</measure>
    <time_frame>End of therapy up to 20 weeks.</time_frame>
    <description>Qualitative feedback regarding the intervention will be sought from therapists and participants using a semi-structured interview. The interview will follow a topic guide aimed at understanding opinions on helpful aspects of the therapy, suggestions for improvement, and the perceived level of social presence (i.e. the subjective experience of being with the non-player characters) in the VR environments. Feedback will be summarised.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Data completion rates.</measure>
    <time_frame>End of therapy up to 20 weeks; follow-up: 6 weeks post-treatment.</time_frame>
    <description>Proportion of questionnaires, assessments and interview appointments completed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homework compliance.</measure>
    <time_frame>End of therapy up to 20 weeks.</time_frame>
    <description>The proportion of homework assignments completed (as indicated by the therapist).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in progress with attaining therapy goals.</measure>
    <time_frame>Baseline; end of therapy up to 20 weeks; follow-up: 6 weeks post-treatment.</time_frame>
    <description>This will be measured using Goal Attainment Scaling (GAS). Goals are agreed at the start of therapy. Initially patients rate the importance, difficulty, and how they are functioning at baseline, for each goal. After therapy patients indicate whether the goal has been achieved and rate the outcome (e.g. +2 better than expected, -2 worse than expected).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety (including social anxiety) and depression levels.</measure>
    <time_frame>Baseline; end of therapy up to 20 weeks; follow-up: 6 weeks post-treatment.</time_frame>
    <description>Measured using the Revised Children's Anxiety and Depression Scale (and Subscales) (RCADS; Chorpita et al. 2000). This is a 47-item self-report questionnaire. Both youth (suitable for ages 8 to 18 years) and parental/caregiver forms will be administered. Participants rate each item using a 4-point Likert scale (0 = Never; 3 = Always). The questionnaires are scored using spreadsheets provided by the developer. A t-score is computed based on the person's school year. T-scores of 70 and higher are classified as clinically significant. Higher t-scores indicate increased symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Global Outcome Ratings of Severity of Illness.</measure>
    <time_frame>Baseline; end of therapy up to 20 weeks; follow-up: 6 weeks post-treatment.</time_frame>
    <description>Measured using the Clinical Global Impression-Improvement Scale (CGI-I; Guy, 1976).
At baseline, the researcher will rate their &quot;impression&quot; of illness severity using baseline qualitative data from the Anxiety Disorders Interview Schedule (ADIS-IV; Albano &amp; Silverman, 1996) on a 7-point Likert scale (1 = normal, not ill at all; 7 = among the most severely ill patients). The ADIS-IV is a semi-structured clinical interview which will be conducted separately with patients and their parents/caregivers (informants).
The same researcher will compare baseline ADIS-IV data with data obtained from a follow-up (qualitative) interview to rate &quot;improvement&quot;. The follow-up interview will be semi-structured, follow a topic guide, and be conducted with the patient and their parent/caregiver (informants) separately. Topics will cover functioning across activities of daily living. &quot;Improvement&quot; will be rated on an 8-point Likert scale (1 = completely recovered; 5 = no change; 8 = very much worse).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Autonomic activity marker: electrodermal activity.</measure>
    <time_frame>First VR exposure session (up to 19 weeks); Final VR exposure session (up to 20 weeks). Timepoints of the first and final VR exposure session will be decided by the therapist case-by-case, see Assigned Intervention for details.</time_frame>
    <description>Obtained from a galvanic skin response sensor on an Empatica E4 wristband taking continuous measurements. Measured in Î¼S. Sampled at 4Hz. Recordings will only be made during the first and final VR exposure sessions. In both sessions, this will involve a 5-minute baseline recording while participants experience a relaxing VR scene. This will be followed by VR exposure for &lt;1 hour during which recordings are also made. A button on the device will be used to timestamp the start and end of VR relaxation/exposure tasks.</description>
  </other_outcome>
  <other_outcome>
    <measure>Autonomic activity marker: Heart rate</measure>
    <time_frame>First VR exposure session (up to 19 weeks); Final VR exposure session (up to 20 weeks). Timepoints of the first and final VR exposure session will be decided by the therapist case-by-case, see Assigned Intervention for details.</time_frame>
    <description>Inter-beat intervals (RR intervals) can be computed from blood volume pulse which will be measured using a photoplethysmography sensor on an Empatica E4 wristband. RR intervals are the successive time difference between heartbeats in ms which can be transformed into beats per minute. Sampled at 64Hz. Recordings will only be made during the first and final VR exposure sessions. In both sessions, this will involve a 5-minute baseline recording while participants experience a relaxing VR scene. This will be followed by VR exposure for &lt;1 hour during which recordings are also made. A button on the device will be used to timestamp the start and end of VR relaxation/exposure tasks.</description>
  </other_outcome>
  <other_outcome>
    <measure>Autonomic activity marker: Heart rate variability (HRV)</measure>
    <time_frame>First VR exposure session (up to 19 weeks); Final VR exposure session (up to 20 weeks). Timepoints of the first and final VR exposure session will be decided by the therapist case-by-case, see Assigned Intervention for details.</time_frame>
    <description>Computed from heart rate measured using a photoplethysmography sensor on an Empatica E4 wristband. Sampled at 64Hz. HRV will be measured by calculating the root mean square of successive RR interval differences (RMSSD). Units: ms. Recordings will only be made during the first and final VR exposure sessions. In both sessions, this will involve a 5-minute baseline recording while participants experience a relaxing VR scene. This will be followed by VR exposure for &lt;1 hour during which recordings are also made. A button on the device will be used to timestamp the start and end of VR relaxation/exposure tasks.</description>
  </other_outcome>
  <other_outcome>
    <measure>Actigraphy: Overall body movement.</measure>
    <time_frame>First VR exposure session (up to 19 weeks); Final VR exposure session (up to 20 weeks). Timepoints of the first and final VR exposure session will be decided by the therapist case-by-case, see Assigned Intervention for details.</time_frame>
    <description>A composite index will be computed for overall body movement during the sampling period using a 3-axis accelerometer. Sampled at 32Hz. Range [-2g, 2g]. An index for overall movement will be extracted using the standard Euclidean metric for each axis sensor at each sampling point and summed for the total recording sample length. Recordings will only be made during the first and final VR exposure sessions. In both sessions, this will involve a 5-minute baseline recording while participants experience a relaxing VR scene. This will be followed by VR exposure for &lt;1 hour during which recordings are also made. A button on the device will be used to timestamp the start and end of VR relaxation/exposure tasks.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjective Units of Distress.</measure>
    <time_frame>First VR exposure session (up to 19 weeks); Final VR exposure session (up to 20 weeks). Timepoints of the first and final VR exposure session will be decided by the therapist case-by-case, see Assigned Intervention for details</time_frame>
    <description>Measured using the Subjective Units of Distress Scale (SUDs; Kim et al., 2008; Wolpe, 1973). This is a self-report scale with ratings ranging from 0 (no distress) to 10 (highest distress/anxiety ever). Ratings acquired every 120 seconds using a visual analogue scale (fear thermometer) in the VR environment. Ratings will only be collected during the first and final VR exposure sessions. In both sessions, this will involve 5-minute baseline ratings while participants experience a relaxing VR scene. This will be followed by VR exposure for &lt;1 hour during which ratings are collected. A button on the device will be used to timestamp the start and end of VR relaxation/exposure tasks.</description>
  </other_outcome>
  <other_outcome>
    <measure>Negative effects from the VR experience.</measure>
    <time_frame>First VR exposure session (up to 19 weeks); Final VR exposure session (up to 20 weeks). Timepoints of the first and final VR exposure session will be decided by the therapist case-by-case, see Assigned Intervention for details</time_frame>
    <description>Measured using the ITC-Sense of Presence Inventory (ITC-SOPI short version; Lessiter et al., 2001). This is a 12-item self-report questionnaire that measures experiences of media. It will be used to measure sense of presence, engagement, ecological validity, and negative effects in the VR environment. For each item, respondents are asked to rate how much they agree or disagree on a 5-point Likert scale (1 = strongly disagree; 5 = strongly agree). The ratings of the three items corresponding to negative effects will be averaged when scored. Higher scores indicated increased negative effects.
This questionnaire will be administered immediately after the first and last VR exposure sessions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Sense of presence in the VR environments.</measure>
    <time_frame>First VR exposure session (up to 19 weeks); Final VR exposure session (up to 20 weeks). Timepoints of the first and final VR exposure session will be decided by the therapist case-by-case, see Assigned Intervention for details</time_frame>
    <description>Measured using the ITC-Sense of Presence Inventory (ITC-SOPI short version; Lessiter et al., 2001). This is a 12-item self-report questionnaire that measures experiences of media. It will be used to measure sense of presence, engagement, ecological validity, and negative effects in the VR environment. For each item, respondents are asked to rate how much they agree or disagree on a 5-point Likert scale (1 = strongly disagree; 5 = strongly agree). The ratings of the three items corresponding to sense of presence will be averaged when scored. Higher scores indicated increased sense of presence.
This questionnaire will be administered immediately after the first and last VR exposure sessions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Engagement in the VR environments.</measure>
    <time_frame>First VR exposure session (up to 19 weeks); Final VR exposure session (up to 20 weeks). Timepoints of the first and final VR exposure session will be decided by the therapist case-by-case, see Assigned Intervention for details</time_frame>
    <description>Measured using the ITC-Sense of Presence Inventory (ITC-SOPI short version; Lessiter et al., 2001). This is a 12-item self-report questionnaire that measures experiences of media. It will be used to measure sense of presence, engagement, ecological validity, and negative effects in the VR environment. For each item, respondents are asked to rate how much they agree or disagree on a 5-point Likert scale (1 = strongly disagree; 5 = strongly agree). The ratings of the three items corresponding to engagement will be averaged when scored. Higher scores indicated increased engagement.
This questionnaire will be administered immediately after the first and last VR exposure sessions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Ecological validity of the VR environments.</measure>
    <time_frame>First VR exposure session (up to 19 weeks); Final VR exposure session (up to 20 weeks). Timepoints of the first and final VR exposure session will be decided by the therapist case-by-case, see Assigned Intervention for details</time_frame>
    <description>Measured using the ITC-Sense of Presence Inventory (ITC-SOPI short version; Lessiter et al., 2001). This is a 12-item self-report questionnaire that measures experiences of media. It will be used to measure sense of presence, engagement, ecological validity, and negative effects in the VR environment. For each item, respondents are asked to rate how much they agree or disagree on a 5-point Likert scale (1 = strongly disagree; 5 = strongly agree). The ratings of the three items corresponding to ecological validity will be averaged when scored. Higher scores indicated increased ecological validity.
This questionnaire will be administered immediately after the first and last VR exposure sessions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of VR exposure.</measure>
    <time_frame>During the intervention.</time_frame>
    <description>Duration the patient spent using VR per session in minutes as estimated by the therapist.</description>
  </other_outcome>
  <other_outcome>
    <measure>The VR environments/scenarios used.</measure>
    <time_frame>During the intervention.</time_frame>
    <description>Using a tick-box approach, the therapists indicates which VR environments/scenarios from the selection provided were used in each session.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <condition>Social Anxiety</condition>
  <arm_group>
    <arm_group_label>Virtual Reality Assisted Cognitive Behavioural Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Between 8 to 20 individual in-person sessions of VR-assisted CBT will be delivered on a weekly basis by NHS therapists who are trained in delivering CBT to this patient group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Virtual Reality Assisted Cognitive Behavioural Therapy</intervention_name>
    <description>The intervention will be delivered in NHS services and will involve using VR to assist the delivery of conventional CBT for the treatment of social anxiety in autistic adolescents. Social situations that are commonly anxiety-evoking for this patient group will be simulated in VR and used for exposure (a typical component of CBT for social anxiety). Therapists will use a modular approach involving optional modules such as psychoeducation on anxiety in the context of ASD, managing expectations of outcome and emotional literacy training. Essential modules include rapport building, introducing the use and purpose of VR, and exposure (incorporating VR). Because CBT is delivered in routine clinical practice, the VR exposure sessions will be the main subject of interest.</description>
    <arm_group_label>Virtual Reality Assisted Cognitive Behavioural Therapy</arm_group_label>
    <other_name>VR-CBT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants will be included at screening if:

          -  Aged between 13 and 18 years

          -  Clinically diagnosed with ASD by a neurodevelopmental clinician

          -  Experiencing anxiety in social situations that is impairing daily functioning as
             determined by clinicians

          -  Deemed suitable by the clinical team for the intervention based on factors such as
             sufficient verbal ability, desire to participate, willingness to undertake
             exposure-based activities, and no current/active suicidal plans.

          -  Able to speak and understand English fluently

          -  Patient and parents/caregivers agree to CBT

        Exclusion Criteria:

        Participants will be excluded at screening if:

          -  Diagnosed with photosensitive epilepsy

          -  Receiving concurrent psychological therapy

          -  Immediate plans are in-place to change their psychopharmacological medication regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucia Valmaggia, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>South London and Maudsley NHS Foundation Trust; King's College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emily Simonoff, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London; South London and Maudsley NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lauren Taylor, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's and St Thomas' NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucia Valmaggia, Dr</last_name>
    <phone>02078485003</phone>
    <email>lucia.valmaggia@kcl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucy Adams, MSc</last_name>
    <phone>0207 848 5717</phone>
    <email>lucy.1.adams@kcl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Thomas Hospital, Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Lauren Taylor, Dr</last_name>
      <phone>0207 188 7188</phone>
      <email>lauren.taylor@gstt.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Lucy Adams, MSc</last_name>
      <phone>0207 848 5717</phone>
      <email>lucy.1.adams@kcl.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Lauren Taylor, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College London</name>
      <address>
        <city>London</city>
        <zip>SE5 8AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Lucia Valmaggia, Dr</last_name>
      <phone>02078485003</phone>
      <email>lucia.valmaggia@kcl.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Lucy Adams, MSc</last_name>
      <phone>0207 848 5717</phone>
      <email>lucy.1.adams@kcl.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Lucia Valmaggia, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emily Simonoff, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucy Adams, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maudsley Hospital, South London and Maudsley NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 8AZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Emily Simonoff, Prof.</last_name>
      <phone>02078485312</phone>
      <email>pa-simonoff@kcl.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Lucy Adams, MSc</last_name>
      <phone>0207 848 5717</phone>
      <email>lucy.1.adams@kcl.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Emily Simonoff, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>March 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>social phobia</keyword>
  <keyword>anxiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

